11th Circ. Rips FDA's 'Invisible Ink' Interpretation Of Drug Act
An Eleventh Circuit judge criticized the U.S. Food and Drug Administration's interpretation of the Orphan Drug Act during oral arguments Tuesday over its approval for two companies to make the same...To view the full article, register now.
Already a subscriber? Click here to view full article